The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Adjuvant nivolumab plus ipilimumab vs placebo for patients with localized renal cell carcinoma at high risk of relapse after nephrectomy: Subgroup analyses from the phase 3 CheckMate 914 (part A) trial.
 
Robert J. Motzer
Consulting or Advisory Role - AstraZeneca; Aveo; Calithera Biosciences; Eisai; EMD Serono; Exelixis; Genentech/Roche; Incyte; Merck; Pfizer
Research Funding - Aveo (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Paul Russo
No Relationships to Disclose
 
Viktor Grünwald
Stock and Other Ownership Interests - AstraZeneca; Bristol-Myers Squibb; Genmab; MSD; Seagen
Honoraria - Advanced Accelerator Applications/Novartis; Apogepha; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; EUSA Pharma; Ipsen; Janssen-Cilag; Merck Serono; MSD Oncology; Nanobiotix; Ono Pharmaceutical; Pfizer
Consulting or Advisory Role - Bristol-Myers Squibb; Cor2Ed; Cureteq; Debiopharm Group; Eisai; Gilead Sciences; Ipsen; Janssen-Cilag; MSD Oncology; Novartis; Oncorena; Onkowissen; PCI Biotech; Pfizer
Research Funding - Amgen (Inst); BMS (Inst); Gilead Sciences (Inst); Ipsen (Inst); MSD Oncology (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Janssen; Merck Serono; Pfizer
 
Yoshihiko Tomita
Honoraria - Astellas Pharma; Bristol-Myers Squibb Japan; Chugai Pharma; Merck; MSD; Ono Pharmaceutical; Pfizer; Takeda
Consulting or Advisory Role - Eisai; MSD; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Chugai Pharma (Inst); Eisai (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Takeda (Inst)
 
Philippe Barthélémy
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Gilead Sciences; Ipsen; Janssen-Cilag; Merck KGaA; MSD; Novartis; Pfizer; Seagen
Consulting or Advisory Role - AAA/Endocyte/Novartis; Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb (Mexico); Eisai; Gilead Sciences; Ipsen; Janssen-Cilag; Merck KGaA; MSD Oncology; Pfizer
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Ipsen; Janssen-Cilag; Merck/Pfizer; MSD; Pfizer
 
Jeffrey C. Goh
Stock and Other Ownership Interests - Icon Cancer Care; Immutep
Honoraria - Ipsen; MSD Oncology
Consulting or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; Janssen Oncology; MSD
Speakers' Bureau - AstraZeneca/MedImmune; Bristol-Myers Squibb; Ipsen; Janssen; MSD Oncology
Research Funding - BeiGene (Inst)
Travel, Accommodations, Expenses - AstraZeneca
 
Hernán Javier Cutuli
Travel, Accommodations, Expenses - Merck Sharp & Dohme; Roche
 
Burcin Simsek
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Julia Spiridigliozzi
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Aleksander Chudnovsky
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Axel Bex
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); Roche/Genentech (Inst)
Speakers' Bureau - Eisai
Research Funding - Pfizer (Inst)